INGN-201. Introgen Therapeutics.
In April 2001, Aventis and Introgen signed a letter of intent to restructure their collaboration arrangement, giving Introgen responsibility for the worldwide development of all p53 programs under the existing collaboration and obtain exclusive worldwide commercial rights to p53-based gene therapy products, including INGN-201. In February 2001, Introgen was awarded US-06194191 for the commercial production of adenovirus vectors. In November 2000, the company and the University of Texas System were issued with US-06143290, entitled 'Recombinant p53 adenovirus methods and compositions', further solidifying the company's current p53 patent portfolio. In June 2000, the University of Texas System was awarded US-06069134, entitled, 'Methods and compositions comprising DNA damaging agents and p53.' This is the second US patent to be issued that is equivalent to WO-09528948. In May 1998, US-05747469, entitled 'Methods and compositions comprising DNA damaging agents and p53', was awarded to the Board of Regents of the University of Texas. This patent covers the use of the p53 gene in combination with chemotherapeutic agents, radiation therapies or other agents, which damage the DNA of cancer cells. It is one of several intellectual properties licensed to Introgen through an agreement with the MD Anderson Cancer Center.
Brukner
I
I
Galileo Genomics, Montreal, Canada. ibrukner@hotmail.com
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D013329:Structure-Activity Relationship